Patient characteristics and outcome, cohort 2

PatientResponseCharacteristics (m1/f2; age (y3))PhototypeHistological typeBRAF Status (wt7/mut8)Checkpoint inhibitor therapyNumber of involved organsMetastasisTumor Response at first CT scan11
1Respondersf, 35n.a.4SSM5mutanti-PD19 + anti-CTLA4104Soft tissue, Lung, Liver, SpleenPR
2m, 932SSMwtanti-PD12Lymph nodes, LungSD*
3f, 492SSMmutanti-PD1 + anti-CTLA44Lung, Liver, Lymph nodes, BrainPR
4f, 433SSMwtanti-PD14Lung, Lymph nodes, Soft tissue, BrainPR
5f, 542SSMmutanti-PD12Soft tissue, Lymph nodesPR
6m, 48n.a.nodularwtanti-PD13Lymph nodes, Soft tissue, BonePR
7m, 572nodularwtanti-PD17Soft tissue, Lymph nodes, Kidney, Peritoneum, Lung, Bone, BrainSD*
8f, 532nodularmutanti-PD11LungSD*
9m, 362nodularwtanti-PD12Lung, Lymph nodesPR
10m, 75n.a.nodularwtanti-PD11LungPR
11m, 692nodularwtanti-PD11Soft tissuePR
12f, 492nodularwtanti-PD11LungPR
13m, 304nodularmutanti-PD11BrainPR
14m, 652naevoidmutanti-PD1 + anti-CTLA44Soft tissue, Lung, Lymph nodes, BrainPR
15Non-Respondersm, 792LMM6wtanti-PD12Lymph nodes, LiverSD*
16f, 522SSMmutanti-CTLA45Soft tissue, Lung, Liver, Mesenterium, BrainPD
17m, 682SSMwtanti-PD18Soft tissue, Lymph nodes, Lung, Suprarenal gland, Liver, Intestinum, Bone, BrainPD
18f, 583nodularmutanti-PD11BrainPD
19m, 853nodularwtanti-PD11BrainPD
20m, 603nodularwtanti-PD1 + anti-CTLA43Lymph nodes, Lung, LiverPD
21m, 75n.a.desmoplasticwtanti-PD12Lymph nodes, LiverPD

* pseudoprogression, 1male, 2female, 3years, 4not applicable, 5superficial spreading melanoma, 6lentigo maligna melanoma, 7wild type, 8V600E mutation, 9anti-programmed-cell-death-protein-1, 10anti-cytotoxic-T-lymphocyte-associated-protein-4, 11 CR Complete Remission, PR Partial Remission, SD Stable Disease, PD Progressive Disease